MANKIND PHARMA
Back to Income Statement
|
MANKIND PHARMA Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹10,260 Cr | ₹874,943 Cr | ₹7,782 Cr | ₹621 Cr | ₹58,719 Cr |
What is the latest Revenue of MANKIND PHARMA ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹10,260 Cr |
| Mar2024 | ₹874,943 Cr |
| Mar2023 | ₹7,782 Cr |
| Mar2022 | ₹621 Cr |
| Mar2021 | ₹58,719 Cr |
How is Revenue of MANKIND PHARMA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹10,260 Cr | -98.83 | |
| Mar2024 | ₹874,943 Cr | 11,143.81 | |
| Mar2023 | ₹7,782 Cr | 1,152.18 | |
| Mar2022 | ₹621 Cr | -98.94 | |
| Mar2021 | ₹58,719 Cr | - | |
Compare Revenue of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹89,742.7 Cr | 1.5% | -2.8% | -19.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,708.0 Cr | -2.9% | -1.8% | -2.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,975.0 Cr | 2.1% | 0.2% | 9.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹128,619.0 Cr | 0.5% | 2.2% | 11.2% | Stock Analytics | |
| CIPLA | ₹122,539.0 Cr | 0.7% | -0.8% | 3.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,741.0 Cr | -0.1% | 2.5% | 2.5% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | 1.5% |
-2.8% |
-19.5% |
| SENSEX | -0.4% |
-0.3% |
3.9% |
You may also like the below Video Courses